| Name | DA-3003-1 |
| Description | DA-3003-1 (DA-3003-1) is a membrane-permeable, potent and selective Cdc25 dual specificity phosphatase inhibitor with antitumor activity that inhibits Cdc25B2, Cdc25A, Cdc25B2 and Cdc25C. |
| In vitro | DA-3003-1(DA-3003-1)(3-100 μM; 48 hours) exhibits an average IC50 value of 1.5 ± 0.6 μM across the NCI 60 cell panel of human tumor types. The IC50 values for human breast cancer MDA-MB-435 and MDA-N cells are 0.2 μM, while in cultured human breast MCF-7 cells, the IC50 value is 1.7 μM[1].
The relative IC50 value of DA-3003-1(DA-3003-1) against Cdc25B2 (IC50=0.21 μM) is lower than that against VHR (IC50 20 times lower and 450 times lower than 4.0 μM) or PTP1B (IC50>4.0 μM)[3]. |
| In vivo | DA-3003-1(DA-3003-1)(intravenous injection; 2, 3, and 5 mg/kg) inhibits the growth of subcutaneous human colon HT29 xenografts in SCID mice. Following a single dose of 5 mg/kg, DA-3003-1(DA-3003-1)is undetectable in plasma or tissues for more than 5 minutes. After treatment of HT29 tumor-bearing SCID mice with DA-3003-1(DA-3003-1), a greater reduction in glutathione concentration is observed in the tumor compared to the liver and kidneys, and this decrease persists for a longer duration[1]. |
| Storage | store at low temperature,keep away from direct sunlight | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | DMSO : 60 mg/mL (186.47 mM), Sonication is recommended.
10% DMSO+40% PEG300+5% Tween 80+45% Saline : 2 mg/mL (6.22 mM), Sonication is recommended.
|
| Keywords | CDC25C | Cdc25B2 | CDC25A |
| Inhibitors Related | MAK-683 hydrochloride | β-Glycerophosphate disodium salt pentahydrate | Hexane-1,6-diol | EPZ015666 | 2-[dodecyl(2-hydroxyethyl)amino]ethanol | Idoxuridine | Cyclosporine | Tartaric acid disodium dihydrate | Stearic acid | L-Ascorbic acid 2-phosphate magnesium | Cyclosporin A | β-Glycerophosphate disodium salt hydrate |
| Related Compound Libraries | Histone Modification Compound Library | Bioactive Compound Library | ReFRAME Related Library | Epigenetics Compound Library | Multi-Target Compound Library | Metabolism Compound Library | Bioactive Compounds Library Max | Covalent Inhibitor Library | Anti-Cancer Compound Library | Phosphatase Inhibitor Library | Anti-Cancer Active Compound Library |
United States
